Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 33 entries
Sorted by: Best Match Show Resources per page
Randomized controlled trial of the NS5A inhibitor daclatasvir plus pegylated interferon and ribavirin for HCV genotype-4 (COMMAND-4).

Antiviral therapy

Hézode C, Alric L, Brown A, Hassanein T, Rizzetto M, Buti M, Bourlière M, Thabut D, Molina E, Rustgi V, Samuel D, McPhee F, Liu Z, Yin PD, Hughes E, Treitel M.
PMID: 26313445
Antivir Ther. 2015 Aug 27;21(3):195-205. doi: 10.3851/IMP2985. Epub 2015 Aug 27.

BACKGROUND: Treatment options for HCV genotype-4 (GT4) are limited. This Phase III study (COMMAND-4; AI444-042) evaluated the efficacy and safety of daclatasvir (DCV), a pan-genotypic HCV NS5A inhibitor, with pegylated interferon-α2a/ribavirin (PEG-IFN/RBV) in treatment-naive patients with HCV GT4 infection.METHODS:...

Cite
Hézode C, Alric L, Brown A, et al. Randomized controlled trial of the NS5A inhibitor daclatasvir plus pegylated interferon and ribavirin for HCV genotype-4 (COMMAND-4). Antivir Ther. 2015;21(3):195-205doi: 10.3851/IMP2985.
Hézode, C., Alric, L., Brown, A., Hassanein, T., Rizzetto, M., Buti, M., Bourlière, M., Thabut, D., Molina, E., Rustgi, V., Samuel, D., McPhee, F., Liu, Z., Yin, P. D., Hughes, E., Treitel, M. (2015). Randomized controlled trial of the NS5A inhibitor daclatasvir plus pegylated interferon and ribavirin for HCV genotype-4 (COMMAND-4). Antiviral therapy, 21(3), 195-205. https://doi.org/10.3851/IMP2985
Hézode, Christophe, et al. "Randomized controlled trial of the NS5A inhibitor daclatasvir plus pegylated interferon and ribavirin for HCV genotype-4 (COMMAND-4)." Antiviral therapy vol. 21,3 (2015): 195-205. doi: https://doi.org/10.3851/IMP2985
Hézode C, Alric L, Brown A, Hassanein T, Rizzetto M, Buti M, Bourlière M, Thabut D, Molina E, Rustgi V, Samuel D, McPhee F, Liu Z, Yin PD, Hughes E, Treitel M. Randomized controlled trial of the NS5A inhibitor daclatasvir plus pegylated interferon and ribavirin for HCV genotype-4 (COMMAND-4). Antivir Ther. 2015 Aug 27;21(3):195-205. doi: 10.3851/IMP2985. Epub 2015 Aug 27. PMID: 26313445.
Copy Download .nbib Format: NLM
16th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV.

Antiviral therapy

[No authors listed]
PMID: 26316027
Antivir Ther. 2014;19:A1-A49.

No abstract available.

Cite
16th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV. Antivir Ther. 2014;19:A1-A49
(2014). 16th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV. Antiviral therapy, 19A1-A49.
"16th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV." Antiviral therapy vol. 19 (2014): A1-A49.
16th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV. Antivir Ther. 2014;19:A1-A49. PMID: 26316027.
Copy Download .nbib Format: NLM
Antiretroviral therapy in resource-limited settings: is there still a role for stavudine?.

Antiviral therapy

Gallant JE.
PMID: 23220760
Antivir Ther. 2012;17(8):1507-9. doi: 10.3851/IMP2498. Epub 2012 Dec 07.

Phanuphak et al. compared three strategies for first-line antiretroviral therapy in 150 Thai patients: initiating therapy with zidovudine (AZT), tenofovir disoproxil fumarate (TDF), or a 24-week lead-in phase with stavudine (d4T) followed by a switch to AZT. Those taking...

Cite
Gallant JE. Antiretroviral therapy in resource-limited settings: is there still a role for stavudine?. Antivir Ther. 2012;17(8):1507-9doi: 10.3851/IMP2498.
Gallant, J. E. (2012). Antiretroviral therapy in resource-limited settings: is there still a role for stavudine?. Antiviral therapy, 17(8), 1507-9. https://doi.org/10.3851/IMP2498
Gallant, Joel E. "Antiretroviral therapy in resource-limited settings: is there still a role for stavudine?." Antiviral therapy vol. 17,8 (2012): 1507-9. doi: https://doi.org/10.3851/IMP2498
Gallant JE. Antiretroviral therapy in resource-limited settings: is there still a role for stavudine?. Antivir Ther. 2012;17(8):1507-9. doi: 10.3851/IMP2498. Epub 2012 Dec 07. PMID: 23220760.
Copy Download .nbib Format: NLM
Correction: DARING-B: discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B.

Antiviral therapy

Papatheodoridis GV, Rigopoulou EI, Papatheodoridi M, Zachou K, Xourafas V, Gatselis N, Hadziyannis E, Vlachogiannakos J, Manolakopoulos S, Dalekos GN.
PMID: 30091421
Antivir Ther. 2018;23(8):711. doi: 10.3851/IMP3261.

No abstract available.

Cite
Papatheodoridis GV, Rigopoulou EI, Papatheodoridi M, et al. Correction: DARING-B: discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B. Antivir Ther. 2018;23(8):711doi: 10.3851/IMP3261.
Papatheodoridis, G. V., Rigopoulou, E. I., Papatheodoridi, M., Zachou, K., Xourafas, V., Gatselis, N., Hadziyannis, E., Vlachogiannakos, J., Manolakopoulos, S., & Dalekos, G. N. (2018). Correction: DARING-B: discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B. Antiviral therapy, 23(8), 711. https://doi.org/10.3851/IMP3261
Papatheodoridis, George V, et al. "Correction: DARING-B: discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B." Antiviral therapy vol. 23,8 (2018): 711. doi: https://doi.org/10.3851/IMP3261
Papatheodoridis GV, Rigopoulou EI, Papatheodoridi M, Zachou K, Xourafas V, Gatselis N, Hadziyannis E, Vlachogiannakos J, Manolakopoulos S, Dalekos GN. Correction: DARING-B: discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B. Antivir Ther. 2018;23(8):711. doi: 10.3851/IMP3261. PMID: 30091421.
Copy Download .nbib Format: NLM
Treatment modification after second-line failure among people living with HIV in the Asia-Pacific.

Antiviral therapy

Jiamsakul A, Azwa I, Zhang F, Yunihastuti E, Ditangco R, Kumarasamy N, Ng OT, Chan YJ, Ly PS, Choi JY, Lee MP, Pujari S, Kiertiburanakul S, Chaiwarith R, Merati TP, Sangle S, Khusuwan S, Sim BL, Avihingsanon A, Duy C, Tanuma J, Ross J, Law M, Asia-Pacific TAHODOI.
PMID: 33843656
Antivir Ther. 2020;25(7):377-387. doi: 10.3851/IMP3388.

BACKGROUND: The World Health Organization recommends continuation with the failing second-line regimen if third-line option is not available. We investigated treatment outcomes among people living with HIV in Asia who continued with failing second-line regimens compared with those who...

Cite
Jiamsakul A, Azwa I, Zhang F, et al. Treatment modification after second-line failure among people living with HIV in the Asia-Pacific. Antivir Ther. 2020;25(7):377-387doi: 10.3851/IMP3388.
Jiamsakul, A., Azwa, I., Zhang, F., Yunihastuti, E., Ditangco, R., Kumarasamy, N., Ng, O. T., Chan, Y. J., Ly, P. S., Choi, J. Y., Lee, M. P., Pujari, S., Kiertiburanakul, S., Chaiwarith, R., Merati, T. P., Sangle, S., Khusuwan, S., Sim, B. L., Avihingsanon, A., Duy, C., Tanuma, J., Ross, J., Law, M., & Asia-Pacific, T. A. H. O. D. O. I. (2020). Treatment modification after second-line failure among people living with HIV in the Asia-Pacific. Antiviral therapy, 25(7), 377-387. https://doi.org/10.3851/IMP3388
Jiamsakul, Awachana, et al. "Treatment modification after second-line failure among people living with HIV in the Asia-Pacific." Antiviral therapy vol. 25,7 (2020): 377-387. doi: https://doi.org/10.3851/IMP3388
Jiamsakul A, Azwa I, Zhang F, Yunihastuti E, Ditangco R, Kumarasamy N, Ng OT, Chan YJ, Ly PS, Choi JY, Lee MP, Pujari S, Kiertiburanakul S, Chaiwarith R, Merati TP, Sangle S, Khusuwan S, Sim BL, Avihingsanon A, Duy C, Tanuma J, Ross J, Law M, Asia-Pacific TAHODOI. Treatment modification after second-line failure among people living with HIV in the Asia-Pacific. Antivir Ther. 2020;25(7):377-387. doi: 10.3851/IMP3388. PMID: 33843656; PMCID: PMC8275121.
Copy Download .nbib Format: NLM
Statin effect on coronary calcium distribution, mass and volume scores and associations with immune activation among HIV+ persons on antiretroviral therapy.

Antiviral therapy

Lipinski J, Margevicius S, Schluchter MD, Wilson DL, McComsey GA, Longenecker CT.
PMID: 33901017
Antivir Ther. 2020;25(8):419-427. doi: 10.3851/IMP3389.

BACKGROUND: Inflammation has been associated with whole heart coronary artery calcification (CAC) among people with HIV (PWH) on antiretroviral therapy (ART); however, prior studies have not evaluated the distribution of calcium or separated mass versus volume scores, which are...

Cite
Lipinski J, Margevicius S, Schluchter MD, et al. Statin effect on coronary calcium distribution, mass and volume scores and associations with immune activation among HIV+ persons on antiretroviral therapy. Antivir Ther. 2020;25(8):419-427doi: 10.3851/IMP3389.
Lipinski, J., Margevicius, S., Schluchter, M. D., Wilson, D. L., McComsey, G. A., & Longenecker, C. T. (2020). Statin effect on coronary calcium distribution, mass and volume scores and associations with immune activation among HIV+ persons on antiretroviral therapy. Antiviral therapy, 25(8), 419-427. https://doi.org/10.3851/IMP3389
Lipinski, Jerry, et al. "Statin effect on coronary calcium distribution, mass and volume scores and associations with immune activation among HIV+ persons on antiretroviral therapy." Antiviral therapy vol. 25,8 (2020): 419-427. doi: https://doi.org/10.3851/IMP3389
Lipinski J, Margevicius S, Schluchter MD, Wilson DL, McComsey GA, Longenecker CT. Statin effect on coronary calcium distribution, mass and volume scores and associations with immune activation among HIV+ persons on antiretroviral therapy. Antivir Ther. 2020;25(8):419-427. doi: 10.3851/IMP3389. PMID: 33901017.
Copy Download .nbib Format: NLM
Correction: Quantitative measurement of HCV core antigen for management of interferon-free therapy in HCV-infected patients.

Antiviral therapy

Łucejko M, Flisiak R.
PMID: 29873634
Antivir Ther. 2018;23(4):383. doi: 10.3851/IMP3242.

No abstract available.

Cite
Łucejko M, Flisiak R. Correction: Quantitative measurement of HCV core antigen for management of interferon-free therapy in HCV-infected patients. Antivir Ther. 2018;23(4):383doi: 10.3851/IMP3242.
Łucejko, M., & Flisiak, R. (2018). Correction: Quantitative measurement of HCV core antigen for management of interferon-free therapy in HCV-infected patients. Antiviral therapy, 23(4), 383. https://doi.org/10.3851/IMP3242
Łucejko, Mariusz, and Flisiak, Robert. "Correction: Quantitative measurement of HCV core antigen for management of interferon-free therapy in HCV-infected patients." Antiviral therapy vol. 23,4 (2018): 383. doi: https://doi.org/10.3851/IMP3242
Łucejko M, Flisiak R. Correction: Quantitative measurement of HCV core antigen for management of interferon-free therapy in HCV-infected patients. Antivir Ther. 2018;23(4):383. doi: 10.3851/IMP3242. PMID: 29873634.
Copy Download .nbib Format: NLM
How can the latent cytomegalovirus cause an increase in all-cause mortality? An answer based on the microcompetition model.

Antiviral therapy

Polansky H.
PMID: 33616550
Antivir Ther. 2020;25(7):349-351. doi: 10.3851/IMP3384.

Many studies showed the existence of a positive association between cytomegalovirus (CMV) seropositivity and all-cause mortality. In this paper, we use the microcompetition model to explain how the latent CMV sequesters the limiting GABP∙p300/CBP transcription complex, which causes abnormal...

Cite
Polansky H. How can the latent cytomegalovirus cause an increase in all-cause mortality? An answer based on the microcompetition model. Antivir Ther. 2020;25(7):349-351doi: 10.3851/IMP3384.
Polansky, H. (2020). How can the latent cytomegalovirus cause an increase in all-cause mortality? An answer based on the microcompetition model. Antiviral therapy, 25(7), 349-351. https://doi.org/10.3851/IMP3384
Polansky, Hanan. "How can the latent cytomegalovirus cause an increase in all-cause mortality? An answer based on the microcompetition model." Antiviral therapy vol. 25,7 (2020): 349-351. doi: https://doi.org/10.3851/IMP3384
Polansky H. How can the latent cytomegalovirus cause an increase in all-cause mortality? An answer based on the microcompetition model. Antivir Ther. 2020;25(7):349-351. doi: 10.3851/IMP3384. PMID: 33616550.
Copy Download .nbib Format: NLM
21st International Workshop on Co-morbidities and Adverse Drug Reactions in HIV.

Antiviral therapy

[No authors listed]
PMID: 31697264
Antivir Ther. 2019;24:A1-A112.

No abstract available.

Cite
21st International Workshop on Co-morbidities and Adverse Drug Reactions in HIV. Antivir Ther. 2019;24:A1-A112
(2019). 21st International Workshop on Co-morbidities and Adverse Drug Reactions in HIV. Antiviral therapy, 24A1-A112.
"21st International Workshop on Co-morbidities and Adverse Drug Reactions in HIV." Antiviral therapy vol. 24 (2019): A1-A112.
21st International Workshop on Co-morbidities and Adverse Drug Reactions in HIV. Antivir Ther. 2019;24:A1-A112. PMID: 31697264.
Copy Download .nbib Format: NLM
Long-term changes in hepatic fibrosis following hepatitis C viral clearance in patients with and without HIV.

Antiviral therapy

Balmaceda JB, Aepfelbacher J, Belliveau O, Chaudhury CS, Chairez C, McLaughlin M, Silk R, Gross C, Kattakuzhy S, Rosenthal E, Kottilil S, Kleiner DE, Hadigan C.
PMID: 31359874
Antivir Ther. 2019;24(4):451-457. doi: 10.3851/IMP3327.

BACKGROUND: While acute changes in hepatic fibrosis are recognized shortly after achieving sustained virological response (SVR) using direct-acting antiviral therapies, long-term outcomes for the growing population of successfully treated patients with HCV remain uncertain. The aim of this study...

Cite
Balmaceda JB, Aepfelbacher J, Belliveau O, et al. Long-term changes in hepatic fibrosis following hepatitis C viral clearance in patients with and without HIV. Antivir Ther. 2019;24(4):451-457doi: 10.3851/IMP3327.
Balmaceda, J. B., Aepfelbacher, J., Belliveau, O., Chaudhury, C. S., Chairez, C., McLaughlin, M., Silk, R., Gross, C., Kattakuzhy, S., Rosenthal, E., Kottilil, S., Kleiner, D. E., & Hadigan, C. (2019). Long-term changes in hepatic fibrosis following hepatitis C viral clearance in patients with and without HIV. Antiviral therapy, 24(4), 451-457. https://doi.org/10.3851/IMP3327
Balmaceda, Julia B, et al. "Long-term changes in hepatic fibrosis following hepatitis C viral clearance in patients with and without HIV." Antiviral therapy vol. 24,4 (2019): 451-457. doi: https://doi.org/10.3851/IMP3327
Balmaceda JB, Aepfelbacher J, Belliveau O, Chaudhury CS, Chairez C, McLaughlin M, Silk R, Gross C, Kattakuzhy S, Rosenthal E, Kottilil S, Kleiner DE, Hadigan C. Long-term changes in hepatic fibrosis following hepatitis C viral clearance in patients with and without HIV. Antivir Ther. 2019;24(4):451-457. doi: 10.3851/IMP3327. PMID: 31359874; PMCID: PMC8296308.
Copy Download .nbib Format: NLM
Correction: A randomized study of standard versus double dose oseltamivir for treating influenza in the community.

Antiviral therapy

Dixit R, Khandaker G, Hay P, McPhie K, Taylor J, Rashid H, Heron L, Dwyer D, Booy R.
PMID: 30358565
Antivir Ther. 2018;23(6):553. doi: 10.3851/IMP3276.

No abstract available.

Cite
Dixit R, Khandaker G, Hay P, et al. Correction: A randomized study of standard versus double dose oseltamivir for treating influenza in the community. Antivir Ther. 2018;23(6):553doi: 10.3851/IMP3276.
Dixit, R., Khandaker, G., Hay, P., McPhie, K., Taylor, J., Rashid, H., Heron, L., Dwyer, D., & Booy, R. (2018). Correction: A randomized study of standard versus double dose oseltamivir for treating influenza in the community. Antiviral therapy, 23(6), 553. https://doi.org/10.3851/IMP3276
Dixit, Rashmi, et al. "Correction: A randomized study of standard versus double dose oseltamivir for treating influenza in the community." Antiviral therapy vol. 23,6 (2018): 553. doi: https://doi.org/10.3851/IMP3276
Dixit R, Khandaker G, Hay P, McPhie K, Taylor J, Rashid H, Heron L, Dwyer D, Booy R. Correction: A randomized study of standard versus double dose oseltamivir for treating influenza in the community. Antivir Ther. 2018;23(6):553. doi: 10.3851/IMP3276. PMID: 30358565.
Copy Download .nbib Format: NLM
Correction: Sofosbuvir-based salvage therapy for HCV infection in cirrhotic patients with DAA failure and multidrug resistance.

Antiviral therapy

Abdurakhmanov DT, Rozina TP, Nikulkina EN, Nabatchikova EA, Chulanov VP, Moiseev SV.
PMID: 30681414
Antivir Ther. 2018;23(8):713. doi: 10.3851/IMP3273.

No abstract available.

Cite
Abdurakhmanov DT, Rozina TP, Nikulkina EN, et al. Correction: Sofosbuvir-based salvage therapy for HCV infection in cirrhotic patients with DAA failure and multidrug resistance. Antivir Ther. 2018;23(8):713doi: 10.3851/IMP3273.
Abdurakhmanov, D. T., Rozina, T. P., Nikulkina, E. N., Nabatchikova, E. A., Chulanov, V. P., & Moiseev, S. V. (2018). Correction: Sofosbuvir-based salvage therapy for HCV infection in cirrhotic patients with DAA failure and multidrug resistance. Antiviral therapy, 23(8), 713. https://doi.org/10.3851/IMP3273
Abdurakhmanov, Dzhamal T, et al. "Correction: Sofosbuvir-based salvage therapy for HCV infection in cirrhotic patients with DAA failure and multidrug resistance." Antiviral therapy vol. 23,8 (2018): 713. doi: https://doi.org/10.3851/IMP3273
Abdurakhmanov DT, Rozina TP, Nikulkina EN, Nabatchikova EA, Chulanov VP, Moiseev SV. Correction: Sofosbuvir-based salvage therapy for HCV infection in cirrhotic patients with DAA failure and multidrug resistance. Antivir Ther. 2018;23(8):713. doi: 10.3851/IMP3273. PMID: 30681414.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 33 entries